Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. / Petterson, Stine Asferg; Sørensen, Mia Dahl; Burton, Mark; Thomassen, Mads; Kruse, Torben A.; Michaelsen, Signe Regner; Kristensen, Bjarne Winther.

In: Brain Pathology, Vol. 33, No. 1, e13111, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Petterson, SA, Sørensen, MD, Burton, M, Thomassen, M, Kruse, TA, Michaelsen, SR & Kristensen, BW 2023, 'Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas', Brain Pathology, vol. 33, no. 1, e13111. https://doi.org/10.1111/bpa.13111

APA

Petterson, S. A., Sørensen, M. D., Burton, M., Thomassen, M., Kruse, T. A., Michaelsen, S. R., & Kristensen, B. W. (2023). Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. Brain Pathology, 33(1), [e13111]. https://doi.org/10.1111/bpa.13111

Vancouver

Petterson SA, Sørensen MD, Burton M, Thomassen M, Kruse TA, Michaelsen SR et al. Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. Brain Pathology. 2023;33(1). e13111. https://doi.org/10.1111/bpa.13111

Author

Petterson, Stine Asferg ; Sørensen, Mia Dahl ; Burton, Mark ; Thomassen, Mads ; Kruse, Torben A. ; Michaelsen, Signe Regner ; Kristensen, Bjarne Winther. / Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. In: Brain Pathology. 2023 ; Vol. 33, No. 1.

Bibtex

@article{0c0159dc1a8d4bccbd97da0b87d8f0b5,
title = "Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas",
abstract = "Glioblastoma is the most common primary malignant brain tumor in adults with an overall survival of only 14.6 months. Hypoxia is known to play a role in tumor aggressiveness but the influence of hypoxia on the immune microenvironment is not fully understood. The aim of this study was to investigate the expression of immune-related proteins in normoxic and hypoxic tumor areas by digital spatial profiling. Tissue samples from 10 glioblastomas were stained with a panel of 40 antibodies conjugated to photo-cleavable oligonucleotides. The free oligo-tags from normoxic and hypoxic areas were hybridized to barcodes for digital counting. Differential expression patterns were validated by Ivy Glioblastoma Atlas Project (GAP) data and an independent patient cohort. We found that CD44, Beta-catenin and B7-H3 were upregulated in hypoxia, whereas VISTA, CD56, KI-67, CD68 and CD11c were downregulated. PD-L1 and PD-1 were not affected by hypoxia. Focusing on the checkpoint-related markers CD44, B7-H3 and VISTA, our findings for CD44 and VISTA could be confirmed with Ivy GAP RNA sequencing data. Immunohistochemical staining and digital quantification of CD44, B7-H3 and VISTA in an independent cohort confirmed our findings for all three markers. Additional stainings revealed fewer T cells and high but equal amounts of tumor-associated microglia and macrophages in both hypoxic and normoxic regions. In conclusion, we found that CD44 and B7-H3 were upregulated in areas with hypoxia whereas VISTA was downregulated together with the presence of fewer T cells. This heterogeneous expression should be taken into consideration when developing novel therapeutic strategies.",
keywords = "digital spatial profiling, glioblastoma, hypoxia, immune checkpoints",
author = "Petterson, {Stine Asferg} and S{\o}rensen, {Mia Dahl} and Mark Burton and Mads Thomassen and Kruse, {Torben A.} and Michaelsen, {Signe Regner} and Kristensen, {Bjarne Winther}",
note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.",
year = "2023",
doi = "10.1111/bpa.13111",
language = "English",
volume = "33",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas

AU - Petterson, Stine Asferg

AU - Sørensen, Mia Dahl

AU - Burton, Mark

AU - Thomassen, Mads

AU - Kruse, Torben A.

AU - Michaelsen, Signe Regner

AU - Kristensen, Bjarne Winther

N1 - Publisher Copyright: © 2022 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.

PY - 2023

Y1 - 2023

N2 - Glioblastoma is the most common primary malignant brain tumor in adults with an overall survival of only 14.6 months. Hypoxia is known to play a role in tumor aggressiveness but the influence of hypoxia on the immune microenvironment is not fully understood. The aim of this study was to investigate the expression of immune-related proteins in normoxic and hypoxic tumor areas by digital spatial profiling. Tissue samples from 10 glioblastomas were stained with a panel of 40 antibodies conjugated to photo-cleavable oligonucleotides. The free oligo-tags from normoxic and hypoxic areas were hybridized to barcodes for digital counting. Differential expression patterns were validated by Ivy Glioblastoma Atlas Project (GAP) data and an independent patient cohort. We found that CD44, Beta-catenin and B7-H3 were upregulated in hypoxia, whereas VISTA, CD56, KI-67, CD68 and CD11c were downregulated. PD-L1 and PD-1 were not affected by hypoxia. Focusing on the checkpoint-related markers CD44, B7-H3 and VISTA, our findings for CD44 and VISTA could be confirmed with Ivy GAP RNA sequencing data. Immunohistochemical staining and digital quantification of CD44, B7-H3 and VISTA in an independent cohort confirmed our findings for all three markers. Additional stainings revealed fewer T cells and high but equal amounts of tumor-associated microglia and macrophages in both hypoxic and normoxic regions. In conclusion, we found that CD44 and B7-H3 were upregulated in areas with hypoxia whereas VISTA was downregulated together with the presence of fewer T cells. This heterogeneous expression should be taken into consideration when developing novel therapeutic strategies.

AB - Glioblastoma is the most common primary malignant brain tumor in adults with an overall survival of only 14.6 months. Hypoxia is known to play a role in tumor aggressiveness but the influence of hypoxia on the immune microenvironment is not fully understood. The aim of this study was to investigate the expression of immune-related proteins in normoxic and hypoxic tumor areas by digital spatial profiling. Tissue samples from 10 glioblastomas were stained with a panel of 40 antibodies conjugated to photo-cleavable oligonucleotides. The free oligo-tags from normoxic and hypoxic areas were hybridized to barcodes for digital counting. Differential expression patterns were validated by Ivy Glioblastoma Atlas Project (GAP) data and an independent patient cohort. We found that CD44, Beta-catenin and B7-H3 were upregulated in hypoxia, whereas VISTA, CD56, KI-67, CD68 and CD11c were downregulated. PD-L1 and PD-1 were not affected by hypoxia. Focusing on the checkpoint-related markers CD44, B7-H3 and VISTA, our findings for CD44 and VISTA could be confirmed with Ivy GAP RNA sequencing data. Immunohistochemical staining and digital quantification of CD44, B7-H3 and VISTA in an independent cohort confirmed our findings for all three markers. Additional stainings revealed fewer T cells and high but equal amounts of tumor-associated microglia and macrophages in both hypoxic and normoxic regions. In conclusion, we found that CD44 and B7-H3 were upregulated in areas with hypoxia whereas VISTA was downregulated together with the presence of fewer T cells. This heterogeneous expression should be taken into consideration when developing novel therapeutic strategies.

KW - digital spatial profiling

KW - glioblastoma

KW - hypoxia

KW - immune checkpoints

U2 - 10.1111/bpa.13111

DO - 10.1111/bpa.13111

M3 - Journal article

C2 - 36093941

AN - SCOPUS:85137851032

VL - 33

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 1

M1 - e13111

ER -

ID: 320645448